健脾活血方联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化的临床疗效分析

Clinical Efficacy Analysis of Invigorating Spleen and Promoting Blood Circulation Recipe Combined with Ursodeoxycholic Acid Capsule in the Treatment of Primary Biliary Cirrhosis

目的研究健脾活血方联合熊去氧胆酸胶囊应用在治疗原发性胆汁性肝硬化中的效果。方法需选取2014年5月-2019年2月在该院接受原发性胆汁性肝硬化治疗的96例患者作为该次研究活动的观察对象,并遵循随机数字表法分为对照组(48例,使用熊去氧胆酸胶囊治疗)与实验组(48例,健脾活血方联合熊去氧胆酸胶囊治疗),比较两组的肝纤维化指标以及肝功能指标。结果①全部患者在治疗前的IV-C(Ⅳ型胶原)指标、LN(层黏连蛋白)指标与HA(肝纤维化指标透明质酸)差异无统计学意义(P>0.05),在分别治疗后,两组的IV-C指标、LN指标、HA指标均有所改善,且实验组患者的IV-C指标、LN指标与HA指标分别为(106.64±19.41)μg/L、(88.85±28.64)μg/L、(172.65±112.46)μg/L,均小于对照组(136.63±21.67)μg/L、(111.82±27.84)μg/L、(275.57±166.51)μg/L(t=7.142、3.984、3.549,P=0.000、0.000、0.001<0.05);②两组患者在接受治疗前的GGT(谷氨酰氨基转移酶)指标、ALP(碱性磷酸酶)指标与ALT(谷丙转氨酶)差异无统计学意义(P>0.05),而在接受治疗后,3项指标均有明显改善,且实验组患者的GGT(谷氨酰氨基转移酶)指标、ALP(碱性磷酸酶)指标与ALT(谷丙转氨酶)指标分别为(210.41±129.28)IU/L、(144.56±115.78)IU/L、(35.78±17.83)IU/L,均小于对照组(264.36±125.68)IU/L、(200.74±120.42)IU/L、(57.87±22.61)IU/L(t=2.073、2.330、5.315,P=0.041、0.022、0.000<0.05)。结论对原发性胆汁性肝硬化患者应用健脾活血方与熊去氧胆酸胶囊进行联合疗法,可以促进患者肝功能的恢复,所以应当推广此治疗方法。

Objective To study the effect of Invigorating Spleen and Promoting Blood Circulation Recipe combined with ursodeoxycholic acid capsule in the treatment of primary biliary cirrhosis.Methods A total of 96 patients who underwent primary biliary cirrhosis in the hospital from May 2014 to February 2019 were selected as the observation objects for this study.They were divided into the control group(48 cases,treated with ursodeoxycholic acid capsules)and the experimental group(48 patients,Invigorating Spleen and Promoting Blood Circulation Recipe combined with ursodeoxycholic acid capsules)according to the random number table method,and liver fibrosis indexes and liver function indexes of the two groups were compared.Results 1.There was no statistically significant difference between the IV-C(type IV collagen)index,LN(laminin)index and HA(liver fibrosis index hyaluronic acid)index of all patients before treatment(P>0.05).After that,the IV-C index,LN index,and HA index of the two groups were improved,and the IV-C index,LN index,and HA index of the experimental group were(106.64±19.41)μg/L,(88.85±28.64))μg/L,(172.65±112.46)μg/L,are smaller than the control group(136.63±21.67)μg/L,(111.82±27.84)μg/L,(275.57±166.51)μg/L(t=7.142,3.984,3.549,P=0.000,0.000,0.001<0.05);2.GGT(glutamyl aminotransferase)index,ALP(alkaline phosphatase)index and ALT(no statistically significant difference in alanine aminotransferase(P>0.05),and after treatment,all three indicators were significantly improved,and the GGT(glutamyl aminotransferase)and ALP(alkaline phosphatase)indicators of patients in the experimental group were significantly improved.And ALT(alanine aminotransferase)indicators were(210.41±129.28)IU/L,(144.56±115.78)IU/L,and(35.78±17.83)IU/L,all smaller than the control group(264.36±125.68)IU/L,(200.74±120.42)IU/L,(57.87±22.61)IU/L(t=2.073,2.330,5.315,P=0.041,0.022,0.000<0.05).Conclusion The combined therapy of Invigorating Spleen and Promoting Blood Circulation Recipe and ursodeoxycholic acid capsule in patients with primary biliary cirrhosis can promote the recovery of liver function,so this treatment method should be promoted.